Y-mAbs Therapeutics, Inc. (27)

Browse by Contract Category

Contracts

Separation Agreement and General Release, effective as of September 22, 2022, between Y-mAbs Therapeutics, Inc. and Claus Juan Mller San Pedro (Filed With SEC on November 7, 2022)
Amendment No. 2, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 9, 2022)
Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2022)
Asset Purchase Agreement by and between Y-mAbs Therapeutics, Inc. and United Therapeutics Corporation dated December 24, 2020 (Filed With SEC on February 19, 2021)
Settlement and Assumption and Assignment of MSK License Agreement and Y-mAbs Sublicense Agreement, dated as of December 2, 2019, by and among the Company, MabVax Therapeutics... (Filed With SEC on December 19, 2019)
Form of Stock Option Grant Notice and Stock Option Agreement for directors under the 2018 Equity Incentive Plan (Filed With SEC on November 7, 2022)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on November 7, 2022)
Form of Retention Bonus Agreement of Y-mAbs Therapeutics, Inc (Filed With SEC on August 8, 2022)
Form of Retention Bonus Agreement of Y-mAbs Therapeutics A/S (Filed With SEC on August 8, 2022)
Retention Bonus Agreement, dated May 30, 2022 by and between EVP and Chief Financial Officer, Bo Kruse and Y-mAbs Therapeutics A/S (Filed With SEC on August 8, 2022)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 8, 2022)
Amendment to Employment Agreement for Dr. Vignesh Rajah, effective as of March 10, 2021 (Filed With SEC on May 9, 2022)
Employment Agreement for Dr. Vignesh Rajah, effective as of June 2, 2020 (Filed With SEC on May 9, 2022)
Amendment to Employment Agreement for Dr. Steen Lisby, effective as of June 1, 2020 (Filed With SEC on May 9, 2022)
Employment Agreement for Dr. Steen Lisby, effective as of August 1, 2017 (Filed With SEC on May 9, 2022)
Amendment No. 1, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 6, 2021)
Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)
Underwriting Agreement, dated February 17, 2021, by and among Y-mAbs Therapeutics, Inc., and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BofA Securities, Inc., as... (Filed With SEC on February 19, 2021)
License Agreement dated December 17, 2020 between Y-mabs Therapeutics, Inc., and SciClone Pharmaceuticals International Ltd (Filed With SEC on December 22, 2020)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, directors) (Filed With SEC on November 5, 2020)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, employees, consultants and service providers other than directors) (Filed With SEC on November 5, 2020)
Master Sponsored Research Agreement effective as of October 7, 2020 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on October 8, 2020)
License Agreement, effective as of April 15, 2020, by and among the Company, Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology (Filed With SEC on April 21, 2020)
Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)
Y-mAbs Sublicense Agreement, dated as of June 27, 2018, by and between the Company and MabVax Therapeutics Holdings, Inc (Filed With SEC on December 19, 2019)
Underwriting Agreement, dated October 29, 2019, by and among the Company and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of... (Filed With SEC on October 31, 2019)
Amended and Restated Sponsored Research Agreement effective as of September 13, 2019 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on September 19, 2019)